UNSPSC 51181630: Thiamazole

This classification denotes an antithyroid agent with the molecular formula C4H6N2S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 554Z48XN5E, chemically known as 1,3-dihydro-1-methyl-2h-imidazole-2-thione but more generally known as methimazole, which bears U.S. National Institutes of Health Compound Identifier 1349907. European Medicines Agency schedules Thiamazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10967MIG.

The term THIAMAZOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methimazole in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.

UNSPSC 51181630 Thiamazole, a Commodity code, covers the procurement of thiamazole, an antithyroid medication used to treat hyperthyroidism and Graves' disease. State and local governments purchase thiamazole primarily through their health departments, correctional facilities, and public health agencies to support inmate medical care, community health clinics, and disease management programs. The product is typically procured as a generic pharmaceutical in tablet form, often as part of broader medication inventory replenishment cycles or standalone health-services contracts.

The source provided does not include a recent-opportunities block identifying specific solicitations, issuing bodies, or geographic regions where thiamazole procurement is currently active. Without documented recent RFP, RFQ, IFB, or ITB activity, no representative opportunities, issuing-body patterns, or geographic concentration can be confirmed at this time.